Video

Dr. Dietrich on Future Research Directions in Lung Cancer

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer. 

Martin Dietrich, MD, PhD, assistant professor, University of Central Florida, fellow, American College of Physicians, Florida Cancer Specialists & Research Institute, discusses future research directions for the treatment of patients with lung cancer. 

A potentially practice-changing trial is the ongoing phase 3 LAURA study (NCT03521154), which is examining the efficacy and safety of osimertinib (Tagrisso) following chemoradiation in patients with stage III unresectable non­–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations, according to Dietrich. Based on data from the phase 3 PACIFIC trial (NCT02125461), it is clear that this subset of patients derives some benefit from additional treatment in this setting, Dietrich adds.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma